Overview

Phase III Clinical Trial of TRAVATAN Z in Ocular Surface Health

Status:
Completed
Trial end date:
2009-09-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of the study is to compare two ophthalmic solutions in patients with open-angle glaucoma or ocular hypertension.
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Alcon Research
Treatments:
Latanoprost
Ophthalmic Solutions
Pharmaceutical Solutions
Travoprost
Criteria
Inclusion Criteria:

- 18 years or older.

- Ocular Surface Disease Index (OSDI) score and corneal fluorescein staining score as
specified in protocol.

- Diagnosis of open-angle glaucoma or ocular hypertension in at least one eye.

- Intraocular pressure (IOP) controlled with latanoprost 0.005% (XALATAN®) for at least
one continuous month prior to Visit 1.

- Willing and able to discontinue use of any topical ocular medicine other than the
study medication for the duration of the study, including artificial tears.

- Best corrected visual acuity of -0.6 logMAR or better in each eye.

- Other protocol-defined inclusion criteria may apply.

Exclusion Criteria:

- Any medical condition (systemic or ophthalmic) that may preclude safe administration
of the test article.

- Use of contact lenses within 30 days of Visit 1.

- Use of contact lenses during the study.

- Participation in an investigational drug or device study within 30 days of entering
this study.

- Other protocol-defined exclusion criteria may apply.